Merve Keskinkilic | Medical Oncology | Best Researcher Award

Posted on by ScienceFather

Dr. Merve Keskinkilic | Medical Oncology | Best Researcher Award

Medical Oncologist, Izmir Democracy University Buca Seyfi Demirsoy Training and Research Hospital Turkey

Merve Keskinkılıç is a dedicated Medical Oncologist at Burdur State Hospital with a strong academic background in Internal Medicine and Medical Oncology. She earned her M.D. from Dokuz Eylul University Faculty of Medicine and completed her Medical Oncology Fellowship at the same institution. Dr. Keskinkılıç has extensive clinical experience, having served as a Research Fellow at Emory University, USA. Fluent in English (C1 Advanced) and proficient in German (Elementary), she actively participates in international oncology research. Her expertise includes clinical trials, cancer treatment strategies, and translational oncology research, contributing significantly to advancements in the field.

Publication Profile

Scopus

Scholar

🎓 Education

Dr. Keskinkılıç completed her high school education at Balıkesir Science High School (2004-2008) before pursuing medicine at Dokuz Eylul University (2008-2014). She participated in an Oncology Exchange Program at Mansoura University, Egypt (2010). She later obtained an Associate Degree in Healthcare Management from Anadolu University (2014-2017). Her residency in Internal Medicine was completed at Celal Bayar University (2015-2016) and Dokuz Eylul University (2016-2019). She pursued a Medical Oncology Fellowship at Dokuz Eylul University (2019-2024) and is currently undertaking a PhD in Basic Oncology at Dokuz Eylul University Oncology Institute (since 2022). She also worked as a Research Fellow at Emory University, USA (2023).

💼 Experience

Dr. Keskinkılıç began her career as a General Practitioner at Balıkesir Susurluk State Hospital (2014-2015) before becoming a Research Assistant in Internal Medicine at Celal Bayar University (2015-2016) and later at Dokuz Eylul University (2016-2019). She served as a Specialist Doctor at Bitlis Mutki State Hospital (2019) and as a Fellow in Medical Oncology at Dokuz Eylul University (2019-2024). Currently, she is a Medical Oncologist at Burdur Public Hospital (2024-2025) and will join Izmir Democracy University Buca Seyfi Demirsoy Training and Research Hospital in 2025.

🏆 Awards & Honors

Dr. Keskinkılıç holds several prestigious certifications, including the Turkish Board of Internal Medicine Certificate (2018), Experimental Animal Use Certificate (2019), Oncology Clinical Research Training Certificate (2020), and ESMO Board of Examination Certificate (2023). She has also completed Good Clinical Practices (ICU) and Clinical Research Training and has received certifications in Research Ethics and Clinical Trials. Her contributions to oncology research and education have been recognized through multiple national and international accolades.

🔬 Research Focus

Dr. Keskinkılıç specializes in clinical oncology research, focusing on urothelial, bladder, gastric, prostate, and lung cancers. She is actively involved in multiple clinical trials, serving as a Sub-Investigator in research projects such as THOR (Urothelial Cancer), Niagara (Bladder Cancer), MK3475-859 (Gastric Cancer), Regeneron (Non-Small Cell Lung Cancer), and Radiant 20510 (Prostate Cancer). Her work emphasizes innovative treatment strategies, immunotherapy, and targeted cancer therapies, contributing to the development of advanced oncological treatments. Her internal medicine dissertation evaluated CMV DNA Antigenemia in Allogeneic Bone Marrow Transplant Patients.

Publication Top Notes

  • Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy
    • Authors: C. Karacin, B. Oksuzoglu, A. Demirci, M. Keskinkılıç, et al.
    • Journal: BMC Cancer, 2023
    • Citations: 20

 

  • Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
    • Authors: S. Kahraman, E. Erul, M. Seyyar, O. Gumusay, et al.
    • Journal: Future Oncology, 2023
    • Citations: 13

 

  • Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: a multicenter study
    • Authors: H. Ç. Yıldırım, E. Mutlu, E. Chalabiyev, M. Özen, et al.
    • Journal: The Breast, 2022
    • Citations: 13

 

  • The effect of low HER2 expression on treatment outcomes in metastatic hormone receptor-positive breast cancer patients treated with a combination of a CDK4/6 inhibitor and…
    • Authors: E. C. Yildirim, E. Atag, E. Coban, et al.
    • Journal: The Breast, 2023
    • Citations: 12

 

  • Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia
    • Authors: H. C. Yildirim, C. Kapar, B. Koksal, et al.
    • Journal: Journal of Chemotherapy, 2024
    • Citations: 4

 

  • The prognostic indicator in breast cancer treated with CDK4/6 inhibitors: the prognostic nutritional index
    • Authors: M. Keskinkilic, H. S. Semiz, G. Polat, et al.
    • Journal: Future Oncology, 2023
    • Citations: 4

 

  • Antibody-Drug Conjugates in Triple Negative Breast Cancer
    • Authors: M. Keskinkilic, R. Sacks
    • Journal: Clinical Breast Cancer, 2024
    • Citations: 3

 

  • 194P Increased blood creatinine level due to CDK 4/6 inhibitor treatments: single center experience
    • Authors: M. Keskinkılıç, H. S. Semiz, T. Yavuzsen, A. Karaoglu
    • Journal: Annals of Oncology, 2022
    • Citations: 3

 

  • The prognostic nutritional index (PNI): A new biomarker for determining prognosis in metastatic castration-sensitive prostate carcinoma
    • Authors: H. I. Ellez, M. Keskinkilic, et al.
    • Journal: Journal of Clinical Medicine, 2023
    • Citations: 11

 

  • The role of immune checkpoint inhibition in triple-negative breast cancer
    • Authors: K. Tarekegn, M. Keskinkilic, T. J. Kristoff, S. T. Evans, K. Kalinsky
    • Journal: Expert Review of Anticancer Therapy, 2023
    • Citations: 10

 

  • The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer
    • Authors: M. Hizal, B. Bilgin, N. Paksoy, et al.
    • Journal: Journal of Cancer Research and Clinical Oncology, 2023
    • Citations: 5

 

  • CD47 (‘don’t eat me’ signal) expression levels and its relationship with clinicopathologic features in early‐stage prostate carcinoma
    • Authors: H. S. Semiz, Ü. Küçük, E. Kısa, M. Keskinkılıç, et al.
    • Journal: The Prostate, 2022
    • Citations: 5

 

  • A severe case of levothyroxine intoxication successfully treated in intensive care unit
    • Authors: Y. Savran, T. Mengi, M. Keskinkilic
    • Journal: Journal of Acute Disease, 2018
    • Citations: 11

 

 

AYOUB MARHOU | Medical physics| Young Scientist Award

Posted on by ScienceFather

Mr. AYOUB MARHOU | Medical physics| Young Scientist Award

Faculty of sciences, Mohammed first university Morocco

Marhou Ayoub, born on September 28, 1996, in Talsint, Morocco, is a dedicated Ph.D. candidate in Physics and Engineering at the Faculty of Sciences, Oujda. His expertise lies in theoretical physics and particle physics, driven by a strong academic background and research passion.

Professional Profile 

Education 🎓

2024: Final year of Doctorate in Physics and Engineering, Faculty of Sciences, Oujda. 2019: Began Ph.D. in Theoretical Physics and Particle Physics. 2019: Master’s in Physics of Matter and Radiation, Faculty of Sciences, Oujda (Bien). 2017: Bachelor’s in Physics, Faculty of Sciences, Oujda (Bien). 2014: Baccalauréat, Experimental Sciences, Benitadjit (Passable).

Experience 💻

2019: Radiotherapy internship (4 months), Hassan II Oncology Center, CHU Mohammed VI, Oujda. Proficient in Windows, Linux, UNIX, Microsoft Word, LibreOffice, and LaTeX2e. Skilled in programming languages: Fortran (learning), C, C++, and OOP. Expert in simulation tools like Geant4.

Awards and Honors 🏅

  • Recognized for academic excellence in Master’s and Bachelor’s studies.
  • Active contributor to high-level physics research projects and simulations.

Research Focus 🔬

Specializes in theoretical physics, particle physics, and radiation physics, emphasizing advanced computational simulations and programming to explore innovative solutions in physics and engineering.

Publications Top Noted

 

  1. The Impact Assessment of a Magnetic Field Dedicated to MRI During a Carbon-Therapy on Treatment Efficiency: Application to 1.5 T Magnetic Field
    • Authors: A. Marhou, A. Bazza, I. Habib-Allah, M. Zerfaoui, N. Chafi
    • Journal: Radiation Physics and Chemistry
    • Year: 2025
    • Volume: 227
    • Article ID: 112360
    • Citations: 0

 

  1. Assessment of Natural Radioactivity in Moroccan Bottled Drinking Waters Using Gamma Spectrometry
    • Authors: A. Bazza, M. Rhiyourhi, A. Marhou, M. Hamal
    • Journal: Environmental Monitoring and Assessment
    • Year: 2023
    • Volume: 195
    • Issue: 11
    • Article ID: 1307
    • Citations: 1

Jessica Abene| Oncology| Best Researcher Award

Posted on by ScienceFather

Ms. Jessica Abene| Oncology| Best Researcher Award

Ms. University of Pennsylvania,  United States

Jessica Abene is a dedicated nursing professional with a passion for advancing healthcare through evidence-based research. She earned her Bachelor of Nursing Science (BSN) from the University of Pennsylvania in 2023 and is currently pursuing a Master’s in Statistics and Data Science, as well as a PhD. Jessica is deeply engaged in research focused on improving patient care, particularly in oncology and eating disorders. She is an author of several publications, including systematic reviews on chemotherapy toxicities, food insecurity, and binge eating. Her expertise extends to clinical trials and the development of innovative healthcare solutions, such as a smart swaddle for infants with neonatal abstinence syndrome. Jessica is committed to improving patient quality of life through her work as a graduate research assistant and peer reviewer.

Profile

Scopus

🎓 Education

University of Pennsylvania Bachelor of Nursing Science (BSN), 2023. Master of Statistics and Data Science, In Process. Doctor of Philosophy, In Process

💼 Experience

Graduate Research Assistant, University of Pennsylvania, 2021-Present Jessica leads research on diet interventions to alleviate chemotherapy toxicities, coordinates data for clinical trials, and manages a systematic review on food insecurity and binge eating. Peer Reviewer, European Journal of Oncology Nursing, 2024-Present Evaluates submissions for scientific rigor, providing feedback to improve clarity and validity. Penn Nursing Innovation Accelerator Awardee, 2022 Led a team to develop a smart swaddle for infants with neonatal abstinence syndrome, offering comfort and distress relief.

🏆 Awards & Honors

Best Review Paper, International Journal of Eating Disorders (2023) Recognized for outstanding scholarly work as an early career scholar. Rita and Alex Hillman Foundation Pilot Award ($5,000) Awarded for innovative healthcare research. Doctoral Student Organization Research Grant ($325) Provided funding to support academic research. Penn Nursing Innovation Accelerator Awardee ($2,500) Awarded for leading an innovation team developing a smart swaddle system. Eastern Nursing Research Society Annual Conference Abstract Presentation (2023) Presented impactful research findings.

🔬 Research Focus

Jessica’s research aims to improve patient outcomes through evidence-based interventions. She is particularly focused on the impact of diet on chemotherapy toxicities and quality of life, as well as the relationship between food insecurity and binge eating disorders. Additionally, she coordinates clinical trials and studies exploring the effects of lymphedema and fibrosis treatment. Her innovative work includes developing a smart swaddle system for infants with neonatal abstinence syndrome (NAS). Jessica’s research seeks to create practical solutions for complex health challenges and contribute to enhancing patient care in diverse clinical settings.

🏆Conclusion 

Jessica Abene’s combination of rigorous academic training, innovative research, and leadership in healthcare makes her a standout candidate for the Best Researcher Award. Her systematic reviews, dedication to improving patient quality of life, and groundbreaking work in the intersection of healthcare and technology reflect her potential to make significant contributions to the nursing field. Continuing to expand her research network and engaging more broadly with the community will further enhance her already impressive career trajectory.

Publication

  • Dietary Interventions for Alleviating Chemotherapy Toxicities in Patients with Cancer: A Systematic Review
    Year: 2024
    Authors: Abene, J. & Deng, J.
    Status: In process

 

  • Diet as an Adjunct Therapy in Reducing Chemotherapy Toxicities and Improving Patients’ Quality of Life: A Systematic Review and Meta-Analysis
    Year: 2024
    Authors: Abene, J., Tyburski, S., Kral, T. V. E., Quinn, R., & Deng, J.
    Journal: Nutrition and Cancer, 1–19
    DOI: 10.1080/01635581.2024.2437833

 

  • Food Insecurity and Binge Eating: A Systematic Review and Meta-Analysis
    Year: 2023
    Authors: Abene, J. A., Tong, J., Minuk, J., Lindenfeldar, G., Chen, Y., & Chao, A. M.
    Journal: The International Journal of Eating Disorders, 56(7), 1301–1322

 

  • Binge Eating Disorder and Eating Self-Efficacy in Adults Seeking Bariatric Surgery
    Year: 2022
    Authors: Chao, A. M., Abene, J., Allison, K. C., Pearl, R. L., Wadden, T. A., Williams, N. N., & Tronieri, J. S.
    Journal: Clinical Obesity, e12531
    DOI: 10.1111/cob.12531

 

  • The Importance of Student Nursing and Engineering Collaborations
    Year: 2022 (May 20)
    Authors: Leary, M., Abene, J.
    Journal: American Nurse

 

Fabiana Tortora | Cancer | Women Researcher Award

Posted on by ScienceFather

Dr. Fabiana Tortora | Cancer | Women Researcher Award 

Dr. Fabiana Tortora is a Postdoctoral Researcher at the Institute of Genetics and Biophysics (IGB-ABT), CNR, Naples, Italy. With expertise in molecular biology and biochemistry, her research focuses on protein interactors of long non-coding RNAs in bladder cancer and their therapeutic potential. She has presented at numerous international conferences and published extensively in peer-reviewed journals. Dr. Tortora’s work bridges molecular mechanisms and clinical applications, contributing to advancements in cancer research and environmental biochemistry.

Profile

Scopus

🎓 Education

Ph.D. in Biochemical and Biotechnological Sciences: University of Campania Luigi Vanvitelli (2019). Master’s Degree in Biology (LM-6): University of Naples “Federico II” (2016), graduated 110 cum laude. Undergraduate Training: Specialization in molecular biochemistry and precision medicine. Academic projects focused on antioxidant assays, DNA/RNA analysis, and apoptosis markers.

🧑‍🏫 Experience

Postdoctoral Fellow: AIRC-funded project on bladder cancer, IGB-ABT, CNR (2023-2026). Research Grant Recipient: IBP Institute, CNR, Naples (2020-2022). Visiting Scientist: Zewail City of Science and Technology, Egypt (2021). Internship: University of Tübingen, Germany (2018); Campania Luigi Vanvitelli (2016). Expertise in cell cultures, protein purification, FACS, and PCR.

🏆 Awards and Honors

Ph.D. Excellence: University of Campania Luigi Vanvitelli (2019).  Awarded 2022 AIRC Postdoctoral Fellowship for cancer research. Recognized for outstanding research presentations at international conferences. Cum Laude distinction for Master’s degree in Biology.

🔬 Research Focus

Bladder Cancer: Investigating long non-coding RNAs (uc.8+) and their diagnostic/therapeutic potential. Molecular Biochemistry: Protein-DNA/RNA interactions and apoptosis mechanisms. Antioxidant Research: Protective effects of hydroxytyrosol in oxidative stress and mercury detoxification. Techniques: In silico docking, cell/tissue cultures, ROS assays, and enzymatic kinetics.

🏆Conclusion 

Dr. Tortora’s academic rigor, technical proficiency, and impactful research contributions make her a strong contender for the Women Researcher Award. Her work addresses critical biomedical challenges, such as cancer diagnostics and environmental toxicology, underscoring her relevance in both clinical and ecological contexts. By broadening her collaborations and enhancing publication impact, Dr. Tortora can further solidify her position as a leading researcher. She exemplifies excellence in research and is well-suited for recognition through this prestigious award.

📚Publications 

  • Prediction of Pesticide Interactions with Proteins Involved in Human Reproduction by Using a Virtual Screening Approach: A Case Study of Famoxadone Binding CRBP-III and Izumo
    • Year: 2024
    • Authors: Tortora, F., Guerrera, V., Lettieri, G., Febbraio, F., Piscopo, M.

 

  • Emerging RNA-Based Therapeutic and Diagnostic Options: Recent Advances and Future Challenges in Genitourinary Cancers
    • Year: 2023
    • Authors: Tortora, F., La Civita, E., Trivedi, P., Terracciano, D., Cimmino, A.

 

  • CD33 rs2455069 SNP: Correlation with Alzheimer’s Disease and Hypothesis of Functional Role
    • Year: 2022
    • Authors: Tortora, F., Rendina, A., Angiolillo, A., Febbraio, F., Vitale, E.

 

  • Effects of long non-coding RNAs on androgen signaling pathways in genitourinary malignancies
    • Year: 2021
    • Authors: Tortora, F., Calin, G.A., Cimmino, A.

 

  • Liquid biopsy biomarkers in urine: A route towards molecular diagnosis and personalized medicine of bladder cancer
    • Year: 2021
    • Authors: Ferro, M., La Civita, E., Liotti, A., Cimmino, A., Terracciano, D.

 

  • Novel insights into mercury effects on hemoglobin and membrane proteins in human erythrocytes
    • Year: 2020
    • Authors: Piscopo, M., Notariale, R., Tortora, F., Palumbo, G., Manna, C.

 

  • Hydroxytyrosol decreases phosphatidylserine exposure and inhibits suicidal death induced by lysophosphatidic acid in human erythrocytes
    • Year: 2019
    • Authors: Tortora, F., Notariale, R., Lang, F., Manna, C.

 

  • Phenol-rich feijoa sellowiana (Pineapple guava) extracts protect human red blood cells from mercury-induced cellular toxicity
    • Year: 2019
    • Authors: Tortora, F., Notariale, R., Maresca, V., Piscopo, M., Manna, C.

 

  • Comparative analysis of the effects of olive oil hydroxytyrosol and its 5-S-lipoyl conjugate in protecting human erythrocytes from mercury toxicity
    • Year: 2018
    • Authors: Officioso, A., Panzella, L., Tortora, F., Napolitano, A., Manna, C.

 

Muthyam Sowjanya |Cancer | Women Researcher Award

Posted on by ScienceFather

Dr. Muthyam Sowjanya | Cancer | Women Researcher Award

Dr at Vikrama simhapuri university,  India

Sowjanya Muthyam, Ph.D., is a dedicated and highly skilled scientist with 8 years of expertise in immunology, inflammation, molecular biology, cell biology, and biochemistry. Having worked on diverse research projects, including promoting polythene degradation by Spingomonas bacteria and studying bioactive compound production from fungi, Dr. Muthyam seeks a Scientist position to advance industrial, clinical, and translational research.

Profile

Orcid

Education 🎓

Dr. Muthyam holds a Ph.D. in Biotechnology from Andhra University (2014-2019), where her thesis focused on isolating, purifying, and characterizing novel anticancer compounds from Leucas indica flowers. She also completed her M.Sc. in Biotechnology from SRM University (2009-2011), where she studied shell loss in P. monodon and the antiglycation effects of spices. She holds a B.Sc. in Biotechnology, Chemistry, and Computer Applications from Sri Venkateswara University (2006-2009).

Research Experience 💼

Dr. Muthyam’s doctoral research involved isolating and characterizing bioactive compounds from Leucas indica, revealing an anticancer compound that inhibited cancer cell proliferation, particularly in MCF-7 and HeLa cell lines. Her work involved various techniques like column chromatography, UV, TLC, NMR, and apoptosis assays, contributing significantly to cancer treatment strategies. She also collaborated on projects related to bioremediation and bioactive compound production.

Awards 🏆

Dr. Muthyam has received the UGC RGNF fellowship as a Junior Research Fellow (2014-2016) and a Senior Research Fellow (2016-2019). She has also mentored graduate and undergraduate students, supervised research projects, and served as a judge for research poster presentations. Her contributions to the field have earned recognition within the scientific community, particularly for her work on novel anticancer compounds.

Research Focus 🔍

Dr. Muthyam’s primary research focuses on the isolation and characterization of bioactive compounds, with a strong emphasis on anticancer agents. Her work also explores bioremediation strategies, enzyme production, and the application of fungi in industrial processes. Dr. Muthyam is particularly interested in advancing molecular biology, immunology, and biochemistry to develop therapeutics for cancer treatment and environmental sustainability.

Teaching and Mentoring Experience🧑‍🏫

Dr. Muthyam has a solid background in teaching and mentoring, having supervised over 40 graduate students and interns at Andhra University. She has also mentored numerous undergraduate students and evaluated their research poster presentations. Additionally, she is currently serving as a guest faculty member at Vikrama Simhapuri University, where she continues to guide students in research and development.

Conclusion 📝

Dr. Sowjanya Muthyam stands out as a promising researcher with a solid academic foundation, innovative research achievements, and a passion for mentoring the next generation of scientists. Her work, particularly in cancer treatment and bioactive compounds, holds immense potential for future clinical and industrial applications. By focusing on expanding her publication record, collaborations, and public engagement, she can significantly enhance her impact in the scientific community. Dr. Muthyam is a strong candidate for the Women Researcher Award, and her continued contributions will undoubtedly advance the fields of biotechnology and molecular medicine.

Publications 📚

  1. Probiotics Contribution to the Development of Aquaculture: A Review
    • Journal: African Journal of Biological Sciences
    • Date: 2024-07-20
    • Contribution: Sowjanya Muthyam

 

  1. Immobilisation of Aspergillus flavus Strain S4 Spores for Optimal Production and Activity of L-Glutaminase
    • Journal: Chelonian Conservation and Biology
    • Date: 2023-11-11
    • Contribution: Sowjanya Muthyam

 

  1. Incidence of White Feces Syndrome (WFS) and Its Management with Herbal Supplements (Allium sativum and Curcuma longa) by Improving the Growth and Gut Health of Shrimp Litopenaeus vannamei (Boone-1931)
    • Journal: IJFANS International Journal of Food and Nutritional Sciences
    • Date: 2023-11-11
    • Contribution: Sowjanya Muthyam

 

  1. Industrial Applications of Alkaline Protease with Novel Properties from Bacillus cereus Strain S8
    • Date: 2023-11-07
    • Contribution: Sowjanya Muthyam

 

  1. Phytochemical Analysis and Antimicrobial Activity of Muntingia calabura
    • Journal: Journal of Chemical Health Risks
    • Date: 2023-11-07
    • Contribution: Sowjanya Muthyam

 

  1. Characterization of Alkaline Protease from Bacillus cereus Strain S8 by In Silico Approach
    • Journal: Chelonian Conservation and Biology
    • Date: 2023-11-02
    • Contribution: Sowjanya Muthyam

 

  1. In Vitro Antibacterial Activity of Flower Extract of Leucas indica
    • Journal: Journal of Advanced Zoology
    • Date: 2023-11-02
    • Contribution: Sowjanya Muthyam

 

  1. Antiglycation Effect of Chillies and Spices Used in Traditional Indian Cuisine
    • Journal: European Journal of Biomedical and Pharmaceutical Sciences
    • Date: 2023-10-22
    • Contribution: Sowjanya Muthyam

 

  1. Purification, Characterization Studies of L-Glutaminase from Aspergillus flavus Strain S4
    • Journal: Journal of Advanced Zoology
    • Date: 2023-10-01
    • Contribution: Sowjanya Muthyam

 

  1. Probiotics and Their Prolific Role in Shrimp Farming Practices
  • Date: 2022-12-26
  • Contribution: Sowjanya Muthyam

 

TANUMA MISTRY | CLINICAL ONCOLOGY | Best Researcher Award

Posted on by ScienceFather

Dr. TANUMA MISTRY | CLINICAL ONCOLOGY | Best Researcher Award

 

Ms at CHITTARANJAN NATIONAL CANCER INSTITUTE, India

Tanuma Mistry is a dedicated research fellow in the Department of Pathology and Cancer Screening at Chittaranjan National Cancer Institute, Kolkata, India. She holds a Master of Science in Zoology from the University of Calcutta, with extensive research experience in life sciences, specifically cancer research. Tanuma has received prestigious awards, including the SERB International Travel and CSIR-Foreign Travel Grant. She is a member of notable societies such as ESMO, ASCO, and AACR. Tanuma’s research focuses on molecular techniques and targeted therapeutics, contributing significantly to various high-impact publications in the field of oncology.

profile

Scopus

Academic Qualification:🎓

Master of Science (2016): M.Sc. in Zoology from University of Calcutta, Kolkata, India.  Marks obtained: 75.1%. Bachelor of Science (2013):
B.Sc. in Zoology from University of Calcutta (Vidyasagar College for Women), Kolkata, India. Marks obtained: 68%. Higher Secondary Examination (10+2): West Bengal Council of Higher Secondary Education (WBCHSE), Kolkata, India. Ariadaha Sarbamangala Balika Vidyalaya
Marks obtained (Best of 4): 70.75%. Secondary Examination (10): West Bengal Board of Secondary Education (WBBSE), Kolkata, India.
Ariadaha Sarbamangala Balika Vidyalaya Marks obtained: 71.75%

Other Qualification:🧬

CSIR NET-JRF (June 2018) in Life Science (AIR-118). West Bengal State Eligibility Test (WBSET) 2018 in Life Science The Graduate Aptitude Test in Engineering (GATE)-XL 2022 in Life Science

Awards:🏅

SERB International Travel: ESMO Asia Congress 2023, Singapore. CSIR-Foreign Travel Grant: EBCC-13; Barcelona, Spain. 13th East Zonal Oncology Symposium 2024: 2nd Position in Poster Presentation

Membership of Societies:

The Zoological Society, Kolkata,  European Society of Medical Oncology (ESMO) [Id: 561295], 🇺🇸 American Society of Clinical Oncology (ASCO) [Id: 7278374],  American Association for Cancer Research (AACR) [Id: 1304687]

Research Experience:🔬

2019 – Till Date: CSIR Research Fellow Department of Pathology & Cancer Screening, Chittaranjan National Cancer Institute
Registered under Jadavpur University, Department of Life Science and Biotechnology, Kolkata, India

Skills in Laboratory Techniques:

Molecular techniques: Isolation of DNA, RNA, and Protein, PCR, RFLP, RT-PCR, Electrophoresis, Immunohistochemistry, Western Blotting, Northern Blotting, Southern Blotting, DNA sequencing, MTT assay. Computational skills: Operating systems: Windows, Mac Software: Microsoft Office, Statistical Software Sigma Graph & Plot, GraphPad Prism, SPSS, Mendeley, EndNote

Review during M.Sc:

Behavioral Ecology and Conservation Strategies of Greater One-horned Rhinoceros (Rhinoceros unicornis):
Under the Supervision of Dr. Rakesh Tamang

Project during M.Sc:

Localized Survey of Two Important Bio-resources (TEA & FISH) Types and Practices at Dooars Region of North Bengal:
Under the Supervision of Dr. Sumit Homechoudhury

Publications Top Notes

  • Title: Emerging futuristic targeted therapeutics: A comprising study towards a new era for the management of TNBC
    Authors: Mistry T, Nath A, Pal R, Ghosh S, Sahoo PK, Mahata S, Sarkar S, Choudhury T, Nath P, Alam N, Nasare VD
    Year: 2024
  • Title: Molecular targets and therapeutics in chemoresistance of triple-negative breast cancer
    Authors: Nath A, Mitra S, Mistry T, Pal R, Nasare VD
    Year: 2021
    Journal: Medical Oncology
    DOI: 10.1007/s12032-021-01610-x
  • Title: Mitotic checkpoint defects: en route to cancer and drug resistance
    Authors: Sarkar S, Sahoo PK, Mahata S, Pal R, Ghosh D, Mistry T, Ghosh S, Bera T, Nasare VD
    Year: 2021
  • Title: PIM1/STAT3 axis: a potential co-targeted therapeutic approach in triple-negative breast cancer
    Authors: Mahata S, Sahoo PK, Pal R, Sarkar S, Mistry T, Ghosh S, Nasare VD
    Year: 2022
    Journal: Medical Oncology
  • Title: Assessment of quality of life among advanced ovarian cancer patients in a tertiary care hospital in India
    Authors: Sarkar S, Sahoo PK, Pal R, Mistry T, Mahata S, Chatterjee P, Vernekar M, Mandal S, Bera T, Nasare VD
    Year: 2022
  • Title: Premalignant and malignant lesions of oral cavity in eastern India: a hospital-based study
    Authors: Sahoo PK, Sarkar S, Ghosh D, Mahata S, Pal R, Mistry T, Ghosh S, Roy A, Bucha H, Mandal S, Nasare VD
    Year: 2021
  • Title: Outcome of 3-year follow-up with induction vs first line chemotherapy in oral cancer patients: An observational hospital-based study
    Authors: Sahoo PK, Bhowmick AK, Sarkar S, Mahata S, Pal R, Mistry T, Ghosh S, Choudhury T, Kumar RS, Mandal S, Datta S, Nath P, Mukherjee KK, Nasare VD
  • Title: Polymorphism of transporter genes contributes to variations in treatment outcomes and adverse events in platinum-based chemotherapy-treated oral cancer patients
    Authors: Sahoo PK, Mistry T, Sarkar S, Ghosh D, Mahata S, Pal R, Ghosh S, Roy A, Bucha H, Mandal S, Datta S, Nasare VD
    Year: 2024
  • Title: Impact of Low BMI and Nutritional Status on Quality of Life and Disease Outcome in Breast Cancer Patients: Insights from a Tertiary Cancer Center in India
    Authors: Mistry T, Pal R, Ghosh S, Choudhury T, Mandal S, Nath P, Alam N, Nasare VD
    Year: 2024

 

Angelika Długosz-Pokorska | cancer research | Women Researcher Award

Posted on by ScienceFather

 Dr. Angelika Długosz-Pokorska | cancer research |Women Researcher Award

 Dr at Medical University of Łódź,  Poland

A dedicated researcher and project leader at the Medical University of Lodz, Poland, with expertise in pharmacological characterization and anticancer drug development. As Principal Investigator and Co-investigator, led projects funded by prestigious grants like OPUS and SONATA, focusing on opioid peptide analogs and alpha-methylidene-delta-lactones. Supervising international student exchanges and engaging in expert activities, workshops, and editorial work. Recognized with numerous awards for scientific excellence, including Rector’s Awards and IF=8.638 for publication series on opioid mimetics and glutathione peroxidase. Committed to advancing medical science through innovative research and academic leadership.

Profile

  1. Scopus

 

  1. Orcid

📜 Employment History:

Research Associate (2017-present) Medical University of Lodz, Poland; Faculty of Medicine. Co-investigator (2016-2021)
Project: Rational design and pharmacological characterization of chimeric cyclic opioid peptide analogs targeting multiple receptors
Grant: OPUS 9, project ID 2015/17/B/ST5/00153. Principal Investigator (2016-2021) Project: Analysis of the anticancer activity of new synthetic alpha-methylidene-delta-lactones in selected cell lines Grant: SONATA, project ID 2015/17/D/NZ3/02226. Supervisor, Project Manager, and Principal Investigator (2018-present) Project: Analysis of the anticancer activity and molecular mechanism of action of new hybrid molecules containing uracil skeleton with an exo-cyclic methylene group Grant: PRELUDIUM13, project ID UMO-2017/25/N/NZ3/01039

📚 Short Research Training:

University of Rouen, France (2014) Laboratoire de Neuropsychopharmacologie Expérimentale

🌍 Activities:

  • Expert Activity/Reviewer (2024)
    Platform: Qeios
  • International Student Exchanges and ERASMUS Supervision (2024)
    Engaging in initiatives and participating in European Union programs, overseeing ERASMUS students.
  • Participation in Scientific Workshops and Research Teams (2024)
    Engaging in workshops aimed at exchanging experiences, self-improvement, and organization.
  • Editorial Work (2023-present)
    Journal: Reviewer for Breast Cancer-Tokyo, ISSN 1340-6868, eISSN 1880-4233.

🏆 Awards and Distinctions:

2022: First-level Special Award for Outstanding Didactic Work by Academic Teachers Medical University of Lodz.

2020: Team Distinction from the Faculty of Chemistry Nicolaus Copernicus University in Toruń Rector’s Award Medical University of Lodz Second-degree scientific award for a series of publications titled: ‘Investigation of the Anticancer Properties of Synthetic Analogues of Compounds Isolated from Plants’. (Impact Factor – 8.034). Polish Intelligent Development Award – Nomination.

2019: Investigation of Anticancer Activity of Synthetic Analogues of Methylenolactones”, IF=4.026PTBioch Bursary Scholarship 44th FEBS Congress “From Molecules to Living Systems”. Rector’s Award Medical University of Lodz Second Prize for Publication: ‘Synthetic Analogues of Coumarin as Novel Agents with Anticancer Activity’. (Impact Factor = 4.173). Rector’s Award Medical University of Lodz Team Second award for Publication Series:

2017: Rector’s Award Medical University of Lodz First Prize for Publication Series: “Synthesis and Investigation of Biological Activity of Opioid Mimetics and Glutathione Peroxidase”. (IF=8.638). Rector’s Award Medical University of Lodz Team First Prize for Publication Series: “Anticancer Properties of Novel Synthetic Dicoumarins”. (IF=6.221) “Investigation of Anticancer Activity of Sesquiterpene Lactones”. (IF=4.994)

2016: Rector’s Award Medical University of Lodz First Prize for Publication Series: “Anticancer Properties of Novel Synthetic Lactones in Combination with Known Anticancer Drugs”. (IF = 8.835)

Publications Top Notes 📝

  • Title: Synthesis of New Chiral β-Carbonyl Selenides with Antioxidant and Anticancer Activity Evaluation-Part I
    • Authors: Laskowska, A., Pacuła-Miszewska, A.J., Obieziurska-Fabisiak, M., et al.
    • Journal: Materials
    • Year: 2024
    • Volume: 17
    • Pages: 1–15
    • Summary: This study focuses on the synthesis of new chiral β-carbonyl selenides and evaluates their antioxidant and anticancer activities, providing valuable insights into potential therapeutic agents.

 

  • Title: New Uracil Analog with Exocyclic Methylidene Group Can Reverse Resistance to Taxol in MCF7 Cancer Cells
    • Authors: Długosz-Pokorska, A., Perlikowska, R., Janecki, T., et al.
    • Journal: Biologics: Targets and Therapy
    • Year: 2023
    • Volume: 17
    • Pages: 69–83
    • Summary: This article presents a novel uracil analog with potential to reverse resistance to Taxol in MCF7 cancer cells, indicating its promising role as an anticancer agent.

 

  • Title: New Uracil Analog- U-359 can Reverse Resistance to Taxol in MCF-7 cancer cells
    • Authors: Długosz-Pokorska, A., Perlikowska, R., Janecki, T., et al.
    • Journal: Acta Biochimica Polonica
    • Year: 2023
    • Volume: 70
    • Pages: 56
    • Summary: This study explores another uracil analog’s potential to reverse resistance to Taxol in MCF-7 cancer cells, indicating a promising avenue for further research.

 

  • Title: The Influence of Long Carbon Chains on the Antioxidant and Anticancer Properties of N-Substituted Benzisoselenazolones and Corresponding Diselenides
    • Authors: Pacuła-Miszewska, A.J., Obieziurska-Fabisiak, M., Jastrzębska, A., et al.
    • Journal: Pharmaceuticals
    • Year: 2023
    • Volume: 16
    • Pages: 1–11
    • Summary: This research investigates the impact of long carbon chains on the antioxidant and anticancer properties of N-substituted benzisoselenazolones and corresponding diselenides, providing valuable insights into structure-activity relationships.

 

  • Title: Attachment of Chiral Functional Groups to Modify the Activity of New GPx Mimetics
    • Authors: Laskowska, A., Pacuła-Miszewska, A., Długosz-Pokorska, A., et al.
    • Journal: Materials
    • Year: 2022
    • Volume: 16
    • Pages: 1–14
    • Summary: This study explores the modification of GPx mimetics’ activity through the attachment of chiral functional groups, offering potential strategies for enhancing therapeutic effects.

 

Teng Zhang | Gynecologic Oncology | Young Scientist Award

Posted on by ScienceFather

Ms. ‌Teng Zhang |Gynecologic Oncology |Young Scientist Award 

Ms at Qilu Hospital of Shandong University, China

Ms. Teng Zhang is an accomplished Attending Doctor in the Department of Obstetrics and Gynecology at Qilu Hospital of Shandong University. With a Ph.D. and Master’s degree from Cheeloo College of Medicine, Shandong University, and a Bachelor’s degree from Jining Medical College, Ms. Zhang has extensive experience in clinical practice and research. Notable achievements include publications on cervical cancer in high-impact journals and awards in English teaching competitions. Dr. Zhang’s research focuses on fertility-sparing treatments, m6A methylation, and immune cell variations in cervical cancer, underscoring a strong commitment to advancing women’s health.

Profile

 

🎓 Education Background

Sept. 2015 – Sep. 2018: Ph.D., Cheeloo College of Medicine, Shandong University. Sept. 2013 – Sep. 2015: Master, Cheeloo College of Medicine, Shandong University. Sept. 2008 – Jun. 2013: Bachelor of Medicine, Jining Medical College. Sept. 2005 – Jun. 2008: Qingdao No.2 Middle School

💼 Research/Work Experience

July 2022 – Present: Attending Doctor, Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University. Nov. 2018 – June 2021: Resident, Department of Gynecology and Obstetrics, Qilu Hospital of Shandong University. June 2016 – June 2017: Visiting Scholar, Griffith University, Australia

🏆 Scholarships and Awards

2023: Young Teachers English Teaching Competition, Second Prize, Cheeloo College of Medicine, Shandong University, 2021: The First “Guangzhi Cup” English Teaching Competition in Qilu Hospital of Shandong University, Third Prize, July 2013: Excellent Graduate of Shandong Province, Oct. 2009: National Scholarship

Publications Top Notes 📝

  • Xuji Jiang, Chuanli Feng, Wanying Sun, Teng Zhang*, Baoxia Cui. “The top 100 most cited articles on fertility-sparing treatments for cervical cancer: A bibliometric analysis.” Heliyon, 10(11), 2024.

 

  • Zhonghao Mao, Bingyu Wang, Teng Zhang, Baoxia Cui*. “The roles of m6A methylation in cervical cancer: functions, molecular mechanisms, and clinical applications.” Cell Death and Disease, 2023, 14(734).

 

  • Teng Zhang, Jun Jiao, Xinlin Jiao, Lu Zhao, Xinli Tian, Qing Zhang, Daoxin Ma, Baoxia Cui*. “Aberrant frequency of TNFR2+ Treg and related cytokines in patients with CIN and cervical cancer.” Oncotarget, 2017, 9(4).

 

  • Bingyu Wang, Zhonghao Mao, Jinwen Ye, Xinlin Jiao, Teng Zhang, Qi Wang, Sai Han, Youzhong Zhang, Chunling Wang, Taotao Dong, Baoxia Cui. “Glycolysis Induced by METTL14 Is Essential for Macrophage Phagocytosis and Phenotype in Cervical Cancer.” The Journal of Immunology, 2024, 15(212).

 

  • Zhang W, Tian X, Mumtahana F, Jiao J, Zhang T, Croce K.D., Cui B*. “The existence of Th22, pure Th17 and Th1 cells in CIN and Cervical Cancer along with their frequency variation in different stages of cervical cancer.” BMC Cancer, 2015, 15,717.

 

  • Jun Jiao, Teng Zhang, Xinlin Jiao, Tingting Huang, Lu Zhao, Daoxin Ma, Baoxia Cui*. “hsa_circ_0000745 promotes cervical cancer by increasing cell proliferation, migration, and invasion.” J Cell Physiol, 2019, 1-9.

 

  • Xinlin Jiao, Siying Zhang, Jun Jiao, Teng Zhang, Wenjie Qu, Guy Mutangala Muloye, Beihua Kong, Qing Zhang, Baoxia Cui*. “Promoter methylation of SEPT9 as a potential biomarker for early detection of cervical cancer and its overexpression predicts radioresistance.” Clin Epigenetics, 2019, 11(120).

 

 

Isidoro Gutierrez-Alvarez | Radioactividad ambiental | Best Researcher Award

Posted on by ScienceFather

 Dr. Isidoro Gutierrez-Alvarez | Hematological Disorders | Best Researcher Award

Dr at Isidoro Gutierrez-Alvarez University of Huelva Spain

I began my research career with an internship at the Atmospheric Sounding Station (ESAt) in El Arenosillo, Mazagón (Huelva), part of the National Institute of Aerospace Technology (INTA). During this stay, I applied my programming knowledge to extract meteorological information from NASA’s MERRA-2 model and became familiar with the “Weather Research and Forecasting” (WRF) atmospheric simulation model, widely used for high-resolution atmospheric simulations. This contact with INTA has been maintained throughout my research career, conducting joint studies between the University of Huelva and INTA. 🌦️🌐

Later, I expanded these capabilities with the use of Lagrangian atmospheric dispersion models such as HYSPLIT and FLEXPART, which I used to study in detail the behavior of radon around the city of Huelva. Thanks to these models, we were able to simulate the transport behavior of radon from the phosphogypsum ponds to the city of Huelva, identifying that breeze events allowed the recirculation of air masses and their gradual enrichment in radon. These studies were published in two research articles in first-quartile journals. 🌬️🔍

During my Ph.D., I not only studied atmospheric radon but also the radon exhalation rates from the phosphogypsum repository. During this stage, I designed and built two reference soils for measuring exhalation rates, which are used to calibrate and verify the correct functioning of radon measuring equipment, especially those focused on radon exhalation. These reference soils demonstrated that it is necessary to insert the accumulation chamber a few centimeters when measuring exhalations to avoid significant leaks through the exhalation material itself. This research resulted in two articles, one of which was published in a first-decile journal. 🌱📊

Additionally, due to my knowledge of data analysis and programming, I have closely collaborated on other projects carried out by the FRYMA research group. Notably, I actively participated in obtaining and analyzing results in the works of Dr. Guerrero Márquez. 🤝💻

So far, I have supervised three undergraduate theses (TFG) and two master’s theses (TFM), and another two are expected to be defended in September 2023, totaling seven TFG/TFM. Moreover, I am co-director of a doctoral thesis titled “Development and improvement of techniques to characterize the properties of 222Rn in materials and construction systems; modeling the behavior of 222Rn inside homes,” where I play a major role in the academic supervision due to my familiarity with the subject. 📜🏠

Profile

 

📚Academic Background

Degree University Year
Ph.D. Universidad de Huelva 2020
Master in Renewable Distributed Energy Universidad de Córdoba 2017
Bachelor’s Degree in Physics Universidad de Sevilla 2015

Previous Professional Experience

Period | Position / Institution / Country / Reason for Interruption — | — | — 2016-2020 | Predoctoral Researcher / Universidad de Huelva / Spain 2020-2022 | Postdoctoral Researcher / Universidad de Huelva / Spain 2022 | Postdoctoral Researcher (Margarita Salas Fellowship) / Universidad de Cantabria / Spain 2023-Present | Postdoctoral Researcher (Margarita Salas Fellowship) / Universidad de Huelva / Spain

Publications Top Notes 📝

  1. Greenhouse gases in the tall tower of El Arenosillo station in Southwestern Europe: First-year of measurements
    • Authors: J.A. Adame, R. Padilla, I. Gutiérrez-Álvarez, et al.
    • Journal: Atmospheric Research
    • Year: 2024
    • Volume: 299
    • Article: 107221
  2. Surface ozone trends reversal for June and December in an Atlantic natural coastal environment
    • Authors: J.A. Adame, I. Gutiérrez-Álvarez, A. Notario, M. Yela
    • Journal: Environmental Science and Pollution Research
    • Year: 2024
    • Volume: 31
    • Issue: 11
    • Pages: 17461-17471
  3. Behavior of 222Rn, 220Rn and their progenies along a daily cycle for different meteorological situations: Implications on atmospheric aerosol residence times and Rn daughters’ equilibrium factors
    • Authors: A. Barba-Lobo, I. Gutiérrez-Álvarez, J.A. Adame, E.G. San Miguel, J.P. Bolívar
    • Journal: Journal of Hazardous Materials
    • Year: 2024
    • Volume: 464
    • Article: 132998
    • Citations: 1
  4. Control of Radon Flux of an Inactive Uranium Mill Facility in Spain
    • Authors: I. Fuente, C. Sainz, L. Quindós, et al.
    • Journal: Atmosphere
    • Year: 2023
    • Volume: 14
    • Issue: 10
    • Article: 1536
  5. A methodology to determine 212Pb, 212Bi, 214Pb and 214Bi in atmospheric aerosols; Application to precisely obtain aerosol residence times and Rn-daughters’ equilibrium factors
    • Authors: A. Barba-Lobo, I. Gutiérrez-Álvarez, E.G. San Miguel, J.P. Bolívar
    • Journal: Journal of Hazardous Materials
    • Year: 2023
    • Volume: 445
    • Article: 130521
    • Citations: 5
  6. Surface ozone trends at El Arenosillo observatory from a new perspective
    • Authors: J.A. Adame, I. Gutiérrez-Álvarez, P. Cristofanelli, J.P. Bolívar, M. Yela
    • Journal: Environmental Research
    • Year: 2022
    • Volume: 214
    • Article: 113887
    • Citations: 4
  7. A simple and precise methodology to determine particulate matter mass in atmospheric filters; validation and application cases
    • Authors: A. Barba-Lobo, I. Gutiérrez-Álvarez, J.A. Adame, J.P. Bolívar
    • Journal: Environmental Research
    • Year: 2022
    • Volume: 214
    • Article: 113817
    • Citations: 3
  8. Use of a fuzzy qualitative model to reanalyze radon relationship with atmospheric variables in a coastal area near a NORM repository
    • Authors: I. Gutiérrez-Álvarez, J. Aroba, J.E. Martín, J.A. Adame, J.P. Bolívar
    • Journal: Environmental Technology and Innovation
    • Year: 2022
    • Volume: 28
    • Article: 102619
    • Citations: 2

Shunsuke Suzuki | medical physics | Best Researcher Award

Posted on by ScienceFather

Mr. ‌ Shunsuke Suzuki| | Thermodynamics | Best Researcher Award

Mr at Shonan Kamakura General Hospital,  Japan

 I am an accomplished researcher and academic, currently pursuing a Ph.D. at the Graduate School of Engineering, Kyoto University. With a strong background in radiation therapy and dosimetry, my research has focused on radiation-induced secondary carcinogenesis and the development of precise γ-ray dosimetry methods for boron neutron capture therapy (BNCT). I have published several papers and presented at numerous conferences, contributing to advancements in proton therapy and BNCT. Currently, I am introducing the “nuBeam” accelerator-based BNCT system at Shonan Kamakura General Hospital and continue to innovate in the field of radiation dosimetry and cancer treatment technologies.

Profile

 

Education, Experience, and Academic Achievements 🎓

I conducted research on radiation-induced secondary carcinogenesis during my master’s course at the Graduate School of Medicine, Hokkaido University, and presented my findings at an academic conference. Following my master’s, I joined the Minami-Tohoku Cancer Proton Therapy Center, where I published a paper on radiation-induced secondary carcinogenesis in children due to different proton therapy irradiation methods. Currently, I work at Shonan Kamakura General Hospital, where I am introducing the accelerator-based boron neutron capture therapy system “nuBeam” and presenting research on its initial evaluation at conferences and in scholarly papers. Additionally, I am conducting research on developing γ-ray dosimetry in neutron fields, which has been published and will be presented at an international conference. I am also pursuing a doctoral degree at the Graduate School of Engineering, Kyoto University, and will graduate this year.

Contributions to Research & Development, Innovations, and Extension Activities 🧪

In the realm of boron neutron capture therapy (BNCT), the radiation emitted by the BNCT machine is directly linked to the patient dose. Therefore, accurately evaluating the gamma ray dose through measurement is crucial for introducing BNCT into clinical practice. Measurement methods for gamma ray doses in BNCT fields currently vary among facilities, necessitating a universally applicable and accurate method. In Japan, a custom-built thermoluminescent dosimeter (TLD) (Panasonic, UD-170LS) with beryllium oxide powder in a quartz glass tube is used for 𝛾 dose measurement, but it is no longer manufactured or commercially available. Consequently, I investigated a method combining a commercially available Mg2SiO4:Tb TLD (TOREC, TLD-MSO-S) with a 6LiF sintered capsule, verifying its efficacy for 𝛾 dose measurement in an accelerator-based (AB)-BNCT system.

Publications Top Notes 📝

  1. Initial evaluation of accelerator-based neutron source system at the Shonan Kamakura General Hospital
    • Authors: S. Suzuki, K. Nitta, T. Yagihashi, P. Eide, H. Koivunoro, N. Sato, S. Gotoh, et al.
    • Journal: Applied Radiation and Isotopes
    • Volume: 199
    • Article: 110898
    • Year: 2023

 

  1. Effectiveness of robust optimization against geometric uncertainties in TomoHelical planning for prostate cancer
    • Authors: T. Yagihashi, K. Inoue, H. Nagata, M. Yamanaka, A. Yamano, S. Suzuki, et al.
    • Journal: Journal of Applied Clinical Medical Physics
    • Volume: 24
    • Issue: 4
    • Article: e13881
    • Year: 2023

 

  1. Impact of lifetime attributable risk of radiation-induced secondary cancer in proton craniospinal irradiation with vertebral-body-sparing for young pediatric patients
    • Authors: S. Suzuki, T. Kato, M. Murakami
    • Journal: Journal of Radiation Research
    • Volume: 62
    • Issue: 2
    • Pages: 186-197
    • Year: 2021

 

  1. Evaluation of dose effects of two types of tomotherapy couch and examination of its optimization
    • Authors: S. Suzuki, T. Inoue, A. Yamano, H. Nagata
    • Journal: Journal of the Korean Physical Society
    • Volume: 83
    • Issue: 12
    • Pages: 984-992
    • Year: 2023

 

  1. Optimization of TomoTherapy couch density in the RayStation treatment-planning system
    • Authors: S. Suzuki, T. Inoue, T. Yagihashi, H. Nagata
    • Journal: Journal of the Korean Physical Society
    • Volume: 83
    • Issue: 12
    • Pages: 993-1002
    • Year: 2023

 

  1. Relative Biological Effectiveness Values of Spot-scanning Proton Beam Therapy at Shonan Kamakura General Hospital
    • Authors: S. Shiba, M. Yamanaka, K. Matsumoto, A. Yamano, T. Shimo, S. Suzuki, et al.
    • Journal: in vivo
    • Volume: 37
    • Issue: 3
    • Pages: 1016-1021
    • Year: 2023
    • Abstract: This research investigates the Relative Biological Effectiveness (RBE) values of spot-scanning proton beam therapy at Shonan Kamakura General Hospital. The findings contribute to understanding the biological impact and therapeutic advantages of proton beam therapy in clinical settings.

.